AGP
Artia Global Partners Portfolio holdings
AUM
$389M
This Quarter Return
+18.55%
1 Year Return
+34.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$389M
AUM Growth
+$389M
(+14%)
Cap. Flow
+$10.9M
Cap. Flow
% of AUM
2.8%
Top 10 Holdings %
Top 10 Hldgs %
87.23%
Holding
44
New
10
Increased
9
Reduced
7
Closed
9
Top Buys
| 1 |
Insmed
INSM
|
$43.7M |
| 2 |
argenx
ARGX
|
$36.9M |
| 3 |
VRNA
Verona Pharma
VRNA
|
$36.5M |
| 4 |
Trevi Therapeutics
TRVI
|
$7.18M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$5.6M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$50M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$29M |
| 3 |
Protagonist Therapeutics
PTGX
|
$17.2M |
| 4 |
Arcellx
ACLX
|
$15M |
| 5 |
Merus
MRUS
|
$6.73M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
VRNA
1
Verona Pharma
VRNA
$9.16B
| $87.4M | 21.03% | 924,204 +385,716 | +72% | +$36.5M |
|
|
2
Insmed
INSM
$28.8B
| $75.8M | 18.23% | 752,712 +434,473 | +137% | +$43.7M |
|
|
3
argenx
ARGX
$43.6B
| $43.2M | 10.39% | 78,311 +67,000 | +592% | +$36.9M |
|
4
Soleno Therapeutics
SLNO
$3.6B
| $41.4M | 9.97% | 494,424 -4,049 | -0.8% | -$339K |
|
|
5
Eli Lilly
LLY
$657B
| $23.9M | 5.76% | 30,700 -64,187 | -68% | -$50M |
|
6
Boston Scientific
BSX
$156B
| $16.7M | 4.01% | 155,200 +25,500 | +20% | +$2.74M |
|
|
7
Merus
MRUS
$4.98B
| $15.6M | 3.76% | 296,750 -127,890 | -30% | -$6.73M |
|
8
Quest Diagnostics
DGX
$20.3B
| $14.7M | 3.53% | 81,717 +25,000 | +44% | +$4.49M |
|
9
AstraZeneca
AZN
$248B
| $13.3M | 3.21% | 190,752 | – | – |
|
|
10
Trevi Therapeutics
TRVI
$883M
| $7.18M | 1.73% | +1,311,840 | New | +$7.18M |
|
11
Alnylam Pharmaceuticals
ALNY
$58.5B
| $6.84M | 1.65% | 20,970 -7,630 | -27% | -$2.49M |
|
|
12
Regeneron Pharmaceuticals
REGN
$61.5B
| $5.6M | 1.35% | +10,671 | New | +$5.6M |
|
13
Scholar Rock
SRRK
$3.14B
| $4.47M | 1.08% | 126,285 -45,900 | -27% | -$1.63M |
|
14
Revolution Medicines
RVMD
$7.1B
| $3.83M | 0.92% | 104,190 | – | – |
|
|
SWTX
15
DELISTED
SpringWorks Therapeutics
SWTX
| $3M | 0.72% | 63,930 +10,000 | +19% | +$470K |
|
16
EyePoint Pharmaceuticals
EYPT
$797M
| $2.98M | 0.72% | 316,700 | – | – |
|
17
AbbVie
ABBV
$372B
| $2.69M | 0.65% | +14,500 | New | +$2.69M |
|
18
Viking Therapeutics
VKTX
$3.04B
| $2.56M | 0.62% | 96,479 +6,200 | +7% | +$164K |
|
19
Ascendis Pharma
ASND
$11.8B
| $2.11M | 0.51% | 12,240 +4,800 | +65% | +$828K |
|
20
TG Therapeutics
TGTX
$4.65B
| $1.96M | 0.47% | 54,515 | – | – |
|
21
Vertex Pharmaceuticals
VRTX
$100B
| $1.96M | 0.47% | +4,400 | New | +$1.96M |
|
22
Ultragenyx Pharmaceutical
RARE
$2.89B
| $1.52M | 0.37% | +41,830 | New | +$1.52M |
|
23
United Therapeutics
UTHR
$13.8B
| $1.44M | 0.35% | 5,000 | – | – |
|
|
MREO
24
Mereo BioPharma
MREO
$272M
| $1.29M | 0.31% | 475,361 +54,002 | +13% | +$146K |
|
|
25
Protagonist Therapeutics
PTGX
$3.67B
| $1.27M | 0.31% | 22,951 -310,900 | -93% | -$17.2M |
|